Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.08
AIQ's Cash to Debt is ranked lower than
93% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.91 vs. AIQ: 0.08 )
Ranked among companies with meaningful Cash to Debt only.
AIQ' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.07 Max: N/A
Current: 0.08
Equity to Asset -0.27
AIQ's Equity to Asset is ranked lower than
95% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. AIQ: -0.27 )
Ranked among companies with meaningful Equity to Asset only.
AIQ' s Equity to Asset Range Over the Past 10 Years
Min: -0.39  Med: -0.08 Max: 0.04
Current: -0.27
-0.39
0.04
F-Score: 7
Z-Score: 0.67
M-Score: -3.03
WACC vs ROIC
3.35%
22.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 9.72
AIQ's Operating margin (%) is ranked higher than
73% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.73 vs. AIQ: 9.72 )
Ranked among companies with meaningful Operating margin (%) only.
AIQ' s Operating margin (%) Range Over the Past 10 Years
Min: -39.88  Med: 10.25 Max: 15.96
Current: 9.72
-39.88
15.96
Net-margin (%) 1.94
AIQ's Net-margin (%) is ranked higher than
55% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.90 vs. AIQ: 1.94 )
Ranked among companies with meaningful Net-margin (%) only.
AIQ' s Net-margin (%) Range Over the Past 10 Years
Min: -32.43  Med: 1.27 Max: 4.61
Current: 1.94
-32.43
4.61
ROA (%) 1.65
AIQ's ROA (%) is ranked higher than
58% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.78 vs. AIQ: 1.65 )
Ranked among companies with meaningful ROA (%) only.
AIQ' s ROA (%) Range Over the Past 10 Years
Min: -21.65  Med: 0.98 Max: 3.06
Current: 1.65
-21.65
3.06
ROC (Joel Greenblatt) (%) 23.64
AIQ's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. AIQ: 23.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AIQ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -47.29  Med: 16.89 Max: 26.83
Current: 23.64
-47.29
26.83
Revenue Growth (3Y)(%) -4.70
AIQ's Revenue Growth (3Y)(%) is ranked lower than
71% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. AIQ: -4.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AIQ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4.7  Med: 1.30 Max: 27
Current: -4.7
-4.7
27
» AIQ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

AIQ Guru Trades in Q4 2014

Jim Simons 603,260 sh (+1.86%)
Howard Marks 4,756,491 sh (unchged)
» More
Q1 2015

AIQ Guru Trades in Q1 2015

Jim Simons 611,482 sh (+1.36%)
Howard Marks 4,756,491 sh (unchged)
» More
Q2 2015

AIQ Guru Trades in Q2 2015

Jim Simons 623,425 sh (+1.95%)
Howard Marks 4,756,491 sh (unchged)
» More
Q3 2015

AIQ Guru Trades in Q3 2015

Chuck Royce 33,500 sh (New)
Howard Marks 4,756,491 sh (unchged)
Jim Simons 599,360 sh (-3.86%)
» More
» Details

Insider Trades

Latest Guru Trades with AIQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 8.32
AIQ's P/E(ttm) is ranked higher than
99% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.76 vs. AIQ: 8.32 )
Ranked among companies with meaningful P/E(ttm) only.
AIQ' s P/E(ttm) Range Over the Past 10 Years
Min: 8.24  Med: 23.68 Max: 868.06
Current: 8.32
8.24
868.06
Forward P/E 13.59
AIQ's Forward P/E is ranked higher than
77% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.00 vs. AIQ: 13.59 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 8.20
AIQ's PE(NRI) is ranked higher than
98% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.70 vs. AIQ: 8.20 )
Ranked among companies with meaningful PE(NRI) only.
AIQ' s PE(NRI) Range Over the Past 10 Years
Min: 8.2  Med: 23.85 Max: 781.25
Current: 8.2
8.2
781.25
P/S 0.17
AIQ's P/S is ranked higher than
98% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. AIQ: 0.17 )
Ranked among companies with meaningful P/S only.
AIQ' s P/S Range Over the Past 10 Years
Min: 0.08  Med: 0.59 Max: 1.36
Current: 0.17
0.08
1.36
PFCF 1.89
AIQ's PFCF is ranked higher than
99% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.59 vs. AIQ: 1.89 )
Ranked among companies with meaningful PFCF only.
AIQ' s PFCF Range Over the Past 10 Years
Min: 0.74  Med: 5.07 Max: 28.19
Current: 1.89
0.74
28.19
POCF 0.77
AIQ's POCF is ranked higher than
99% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.42 vs. AIQ: 0.77 )
Ranked among companies with meaningful POCF only.
AIQ' s POCF Range Over the Past 10 Years
Min: 0.44  Med: 2.49 Max: 5.26
Current: 0.77
0.44
5.26
EV-to-EBIT 14.51
AIQ's EV-to-EBIT is ranked higher than
71% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.54 vs. AIQ: 14.51 )
Ranked among companies with meaningful EV-to-EBIT only.
AIQ' s EV-to-EBIT Range Over the Past 10 Years
Min: -342.9  Med: 14.50 Max: 65.9
Current: 14.51
-342.9
65.9
EV-to-EBITDA 6.51
AIQ's EV-to-EBITDA is ranked higher than
86% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.62 vs. AIQ: 6.51 )
Ranked among companies with meaningful EV-to-EBITDA only.
AIQ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.1  Med: 6.20 Max: 10
Current: 6.51
-18.1
10
Current Ratio 1.54
AIQ's Current Ratio is ranked lower than
74% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. AIQ: 1.54 )
Ranked among companies with meaningful Current Ratio only.
AIQ' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 1.58 Max: 2.87
Current: 1.54
1
2.87
Quick Ratio 1.54
AIQ's Quick Ratio is ranked lower than
67% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. AIQ: 1.54 )
Ranked among companies with meaningful Quick Ratio only.
AIQ' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 1.58 Max: 2.87
Current: 1.54
1
2.87
Days Sales Outstanding 55.19
AIQ's Days Sales Outstanding is ranked higher than
63% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.54 vs. AIQ: 55.19 )
Ranked among companies with meaningful Days Sales Outstanding only.
AIQ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.87  Med: 48.08 Max: 52.28
Current: 55.19
40.87
52.28
Days Payable 21.97
AIQ's Days Payable is ranked lower than
85% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.98 vs. AIQ: 21.97 )
Ranked among companies with meaningful Days Payable only.
AIQ' s Days Payable Range Over the Past 10 Years
Min: 18.28  Med: 26.15 Max: 38.18
Current: 21.97
18.28
38.18

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.27
AIQ's Price/Projected FCF is ranked higher than
98% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.07 vs. AIQ: 0.27 )
Ranked among companies with meaningful Price/Projected FCF only.
AIQ' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.17  Med: 0.77 Max: 5.82
Current: 0.27
0.17
5.82
Price/Median PS Value 0.27
AIQ's Price/Median PS Value is ranked higher than
89% of the 238 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.98 vs. AIQ: 0.27 )
Ranked among companies with meaningful Price/Median PS Value only.
AIQ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.18  Med: 1.09 Max: 3.58
Current: 0.27
0.18
3.58
Earnings Yield (Greenblatt) (%) 6.86
AIQ's Earnings Yield (Greenblatt) (%) is ranked higher than
83% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. AIQ: 6.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AIQ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.5  Med: 6.60 Max: 11.2
Current: 6.86
1.5
11.2
Forward Rate of Return (Yacktman) (%) 63.27
AIQ's Forward Rate of Return (Yacktman) (%) is ranked higher than
98% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.69 vs. AIQ: 63.27 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AIQ' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 5  Med: 18.40 Max: 148.5
Current: 63.27
5
148.5

More Statistics

Revenue(Mil) $458
EPS $ 0.83
Beta0.46
Short Percentage of Float3.88%
52-Week Range $6.23 - 25.33
Shares Outstanding(Mil)10.75

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AI6M.Germany,
Alliance HealthCare Services Inc Its diagnostic imaging services include magnetic resonance imaging technology and positron emission tomography/computed tomography services that generate representations of the internal anatomy and convert them to film or digital media. The Company operates in two reportable segments, Imaging and Radiation Oncology. It offers non scan-based services, which comprise the use of imaging systems under a short-term contract. In addition, it provides radiation oncology services that include conventional beam therapy, 3-D conformal radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, stereotactic radiosurgery, low dose rate brachytherapy, and high dose rate brachytherapy for the treatment of cancer; and stereotactic radiation oncology services. Further, the Company offers ancillary services, such as marketing support, education, training, and billing assistance. It provides imaging and therapeutic services through hospitals and clinics, independent imaging and radiation oncology centers, and other healthcare providers on a shared-service and full-time service basis, as well as provides services through fixed-sites, primarily to hospitals or health systems. It competes with RadNet, Inc., Center for Diagnostic Imaging. The Company is subject to federal and state government regulations. It is also subject to various environmental, health, and safety laws regulated by the government.
» More Articles for AIQ

Headlines

Articles On GuruFocus.com
Screening for Stocks Based on Price-to-Free Cash Flow Ratio Nov 18 2015 
Screening for Stocks Based on Price-to-Free Cash Flow Ratio Oct 20 2015 
Screening for Stocks Based on Price to Free-Cash Flow Ratio Sep 18 2015 
Alliance Imaging Inc. Reports Operating Results (10-K) Mar 14 2011 
Alliance Imaging Inc. Reports Operating Results (10-Q) Nov 05 2010 
Alliance Imaging Inc. (AIQ) CEO Paul S Viviano buys 10,000 Shares Aug 09 2010 

More From Other Websites
Alliance HealthCare Services Provides Update on Stockholder Transaction Jan 06 2016
ALLIANCE HEALTHCARE SERVICES, INC Files SEC form 8-K, Other Events, Financial Statements and... Jan 06 2016
Alliance HealthCare Services Provides Update on Stockholder Transaction Jan 06 2016
Alliance HealthCare Services, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 21 2015
ALLIANCE HEALTHCARE SERVICES, INC Financials Dec 08 2015
Do Hedge Funds Love Horizon Technology Finance Corp (HRZN)? Nov 29 2015
Is Alliance HealthCare Services, Inc. (AIQ) A Good Stock To Buy? Nov 22 2015
ALLIANCE HEALTHCARE SERVICES, INC Files SEC form 10-Q, Quarterly Report Nov 09 2015
Edited Transcript of AIQ earnings conference call or presentation 5-Nov-15 10:00pm GMT Nov 06 2015
ALLIANCE HEALTHCARE SERVICES, INC Files SEC form 8-K, Financial Statements and Exhibits Nov 06 2015
Alliance HealthCare posts 3Q profit Nov 05 2015
Alliance HealthCare posts 3Q profit Nov 05 2015
Alliance HealthCare Services Inc Earnings Call scheduled for 5:00 pm ET today Nov 05 2015
Alliance HealthCare Services Reports Third Quarter 2015 Results Nov 05 2015
Alliance HealthCare Services Reports Third Quarter 2015 Results Nov 05 2015
Alliance HealthCare Services Announces New Partnership with Premier Florida Interventional Pain... Nov 04 2015
Alliance HealthCare Services Announces New Partnership with Premier Florida Interventional Pain... Nov 04 2015
Alliance HealthCare Services Schedules Conference Call for Third Quarter 2015 Financial Results Oct 30 2015
Alliance HealthCare Services Schedules Conference Call for Third Quarter 2015 Financial Results Oct 30 2015
Alliance Oncology Enters Agreement to Form Partnership with Pacific Cancer Institute in Maui, HI Oct 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK